The U.S. and Europe are in line to get the first doses of an experimental coronavirus vaccine after a partnership between Pfizer Inc. and BioNTech SE delivered dazzling preliminary results in a large patient trial.
Regulators on both sides of the Atlantic ocean are working to speed a review of th
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
